

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/745,509	11/12/1996	MICHAEL S. FELD	MIT-6186Z	6390
30407 75	90 08/26/2004		EXAM	INER
BOWDITCH & DEWEY, LLP 161 WORCESTER ROAD		SMITH, RUTH S		
P.O. BOX 9320 FRAMINGHAM, MA 01701-9320			ART UNIT	PAPER NUMBER
			3737	*

DATE MAILED: 08/26/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	08/745,509	FELD ET AL.				
Office Action Summary	Examiner	Art Unit				
	Ruth S Smith	3737				
The MAILING DATE of this communication a Period for Reply	ppears on the cover sheet w	ith the correspondence address				
A SHORTENED STATUTORY PERIOD FOR REP THE MAILING DATE OF THIS COMMUNICATION  - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a re - If NO period for reply is specified above, the maximum statutory perions  - Failure to reply within the set or extended period for reply will, by state - Any reply received by the Office later than three months after the mail - earned patent term adjustment. See 37 CFR 1.704(b).	1.136(a). In no event, however, may a eply within the statutory minimum of this will apply and will expire SIX (6) MON tute, cause the application to become Al	reply be timely filed  ty (30) days will be considered timely.  NTHS from the mailing date of this communication.  BANDONED (35 U.S.C. § 133).				
Status		·•				
1)⊠ Responsive to communication(s) filed on <u>02</u>	July 2004.					
3) Since this application is in condition for allow	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims	•					
4) ⊠ Claim(s) 29-34 and 36-38 is/are pending in to 4a) Of the above claim(s) is/are withden 5) □ Claim(s) is/are allowed.  6) ⊠ Claim(s) 29-34,36-38 is/are rejected.  7) □ Claim(s) is/are objected to.  8) □ Claim(s) are subject to restriction and	rawn from consideration.					
Application Papers						
9)☐ The specification is objected to by the Exami	ner.					
10) The drawing(s) filed on is/are: a) □ a	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the						
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the						
Priority under 35 U.S.C. § 119		•				
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume application from the International Bure * See the attached detailed Office action for a life.	ents have been received. ents have been received in A riority documents have beer eau (PCT Rule 17.2(a)).	Application No n received in this National Stage				
Attachment/e)						
Attachment(s)  1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)						
Notice of Draftsperson's Patent Drawing Review (PTO-948)     Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date	Paper No.	(s)/Mail Date Informal Patent Application (PTO-152)				

## Claim Rejections - 35 USC 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 29-34,37 are rejected under 35 U.S.C. 103(a) as being unpatentable over Alfano et al (5,293,872) in view of Lewis et al, Kittrell et al ('404) and Ito or Nagasaki et al. Alfano et al disclose the basic teaching of using a Raman endoscope as a diagnostic tool in examining tissue in vivo. Alfano et al discloses the use of a Nd:YAG laser to excite the tissue. Alfano et al also disclose the use of a broad band light source in order to provide a visible image of the tissue. Lewis et al disclose a spectroscopic imaging device that includes an acousto-optic tunable filter and a focal plane array detector. The focal plane array detector is cooled with liquid nitrogen. The invention of Lewis et al relates to non-invasively collecting images at multiple discreet wavelengths in the visible, infrared or near-infrared region. The device of Lewis et al is applicable to biological materials. Lewis et al disclose forming a plurality of images at different infrared wavelengths as seen in column 12. Lewis et al specifically refers to the use of the spectroscopic imaging device in a microscope but states in column 16 that the invention can be applied to other traditional absorption or emission spectroscopic approaches. Therefore, it would have been obvious to one skilled in the art to have modified Alfano et al such that the detector used is a focal plane array for the advantages disclosed by Lewis et al such as improved spectral and spatial resolution. Furthermore, it should be noted that it is a well known expedient in the art to place the imaging device at the distal end of the endoscope rather than using an optical fiber to transmit the detected radiation to an image sensor. Examples of such are shown in Ito and Nagasaki et al. Kittrell et al disclose the use of a cutoff filter at the distal end of a device used for fluorescence imaging to filter out source wavelengths backscattered toward the detector. It would have been obvious to one skilled in the art

Art Unit: 3737

to have further modified Alfano et al such that the focal plane array sensor is placed at the distal end of the endoscope. The advantage of such is to prevent the quality of pictures from deteriorating due to the breaking of optical fibers. Furthermore, it would have been obvious to one skilled in the art to have placed an optical filter in front of the imaging sensor in order to detect Raman scattered radiation at the desired wavelengths and filter out source wavelengths which would affect the desired results.

Claims 36,38 are rejected under 35 U.S.C. 103(a) as being unpatentable over Alfano et al (5,293,872) in view of Lewis et al, Kittrell et al and Ito or Nagasaki et al as applied to claim 29 above, and further in view of Janes et al. Janes is just one example of many which disclose a optical method of analyzing tissue which includes determining concentrations of a plurality of tissue components. In the absence of any showing of criticality, the specific manner in which the amount of a component of the tissue is determined would have been an obvious design choice of known equivalents in the art. It would have been obvious to one skilled in the art to have further modified the method of Alfano et al such that it includes determining the amount of a plurality of tissue components such as by concentration or percentage. The advantage of such is to provide a more complete analysis of the tissue being evaluated.

## Response to Arguments

Applicant's arguments filed July 2, 2004 have been fully considered but they are not persuasive. In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

## Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Art Unit: 3737

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ruth S Smith whose telephone number is (703) 308-3063. The examiner can normally be reached on M-F 5:30 AM- 2:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler can be reached on (703) 308-3552. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Ruth S Smith Primary Examiner Page 4

Art Unit 3737